OTUB1 (OTU domain-containing ubiquitin aldehyde binding protein 1) is a deubiquitinating enzyme (DUB) that belongs to the ovarian tumor (OTU) domain protease superfamily. Although it has been demonstrated to play important roles in the development of many kinds of cancer, the mechanism of OTUB1 in hepatocellular carcinoma (HCC) is not clear. The aim of this study was to explore the roles of OTUB1 in HCC progression using cell lines and 115 archived HCC samples. In addition, the clinical outcomes were also analyzed with a special focus on OTUB1 expression in HCC samples. In the immunohistochemical study, OTUB1 showed high expression in 60 of the 115 cases (52.2%). The OTUB1 expression level was significantly correlated with many clinicopathological parameters, including TNM stage (P = 0.002), histology stage (P = 0.002), and metastasis/recurrence (P = 0.016). Survival analysis showed that the group with OTUB1 overexpression had significantly shorter overall survival time than the group with OTUB1 downregulation (hazard ratio [HR] = 0.482; confidence interval [CI]: 0.311-0.748; P = 0.001). Multivariate analysis indicated that OTUB1 expression was a significant and independent prognostic parameter (HR = 0.214; CI: 0.126-0.364; P < 0.001) for HCC patients. The ability of HCC cells to undergo proliferation, migration, and invasion was suppressed by disruption of endogenous OTUB1 using short hairpin RNA (shRNA). OTUB1 expression appears to be a new and independent predictor for the prognosis of HCC patients. Overexpression of OTUB1 in HCC could be a novel, effective, and supplementary biomarker for HCC because it plays a vital role in the progression of HCC.
Introduction
Hepatocellular carcinoma (HCC) is a common type of cancer, accounting for more than 782,000 new cases worldwide annually [1] . HCC is considered to be the third most common reason for cancerrelated deaths [2, 3] . Cases of death from HCC in China account for half of all HCC-related deaths worldwide [4] , although in recent years the incidence of HCC in the United States and Europe has gradually increased [5, 6] . Despite advances in diagnostic and therapeutic methods during the past decades, the recurrence rate remains high, up to 50% in 2 years [7, 8] . Because of distant metastasis, the long-term prognosis of HCC is not satisfactory [9] . The insidious onset of earlystage HCC makes it very difficult to diagnose, and many HCC patients have lost the opportunity for surgery at the time of diagnosis because of intrahepatic or distant metastasis [10] . The discovery of novel molecular markers of HCC will provide effective benefits for early diagnosis, targeted therapy, and prognosis of HCC patients.
Ubiquitination is a post-translational modification that regulates a series of biological processes and physiological responses by targeting the substrate protein for degradation, modulating its activity and function, changing its subcellular location, and affecting DNA repair [11, 12] . Deubiquitination can reverse the processes of ubiquitination, and is catalyzed by a superfamily of deubiquitinating enzymes called DUBs. Previous investigations have shown that deubiquitination can promote cancer development and progression [13] . OTUB1 (OTU domain-containing ubiquitin aldehyde binding protein 1; also called Otubain 1) is a member of the ovarian tumor (OTU) domain protease superfamily of DUBs [14] . OTUB1 is normally expressed in several human tissues, e.g. kidney, colorectal, gastric, brain, and liver [15, 16] . The OTUB1 gene is located on human chromosome 11q13.1 and the protein has an OTU domain of 130 amino acids, which are highly conserved from yeast to mammals [17, 18] .
OTUB1 can downregulate ubiquitination and control the stability and activity of proteins by a non-classical mechanism and the traditional catalytic process. More specifically, OTUB1 can act as a cysteine protease that hydrolyzes the isopeptide bond between ubiquitin and the target protein or another ubiquitin molecule [19] . OTUB1 has been implicated in the modulation of physiological and pathological processes. For instance, OTUB1 affects T-cell anergy by GRAIL [20] , enhances transforming growth factor beta (TGF-β) induction and inhibits the ubiquitination of phospho-SMAD2/3 [21] , stabilizes c-IAP1 expression, and facilitates TWEAK-induced activation of the nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways [22] .
In recent years, studies have shown high expression of OTUB1 in tumor tissues of patients with breast cancer, lung cancer, prostate cancer, colon cancer, and ovarian cancer, and demonstrated that OTUB1 overexpression can promote tumor metastasis and is negatively correlated with prognosis and quality of life [17, [23] [24] [25] [26] . However, there is a lack of relevant research concerning OTUB1 in HCC, and the molecular mechanism of OTUB1 in primary HCC is still unclear.
In this study, we examined the relationship between OTUB1 expression and survival in HCC and its effect on the invasion and migration of HCC cells by immunohistochemistry and in vitro cell assays, and provided a new theoretical basis for the early diagnosis and treatment of HCC.
Materials and Methods

HCC patient specimens
To examine the expression of OTUB1 in human HCC, paired adjacent non-tumorous and tumorous HCC specimens were obtained from 115 HCC patients who underwent radical resection without prior chemotherapy or radiotherapy at the Department of General Surgery, Affiliated Hospital of Nantong University. Resected HCC adjacent non-tumor samples and matched tumor tissues were collected and immediately stored in liquid nitrogen. All tissue samples were independently confirmed for grade and histological type by two professional pathologists. All patients provided informed consent and this research was approved by the Human Research Ethics Committee of the Affiliated Hospital of Nantong University (Nantong, China).
HCC cell lines
The human HCC cell lines (SK-hep1, HCCLM3, HepG2, and SMMC7721) were obtained from the Shanghai Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in DMEM (HyClone, Logan City, USA) with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin/streptomycin (Gibco BRL, Grand Island, USA) in a 5% CO 2 humid atmosphere at 37°C.
Western blot analysis
Total protein extracts from cell lines and tumor tissues were prepared using lysis buffer (Beyotime Institute of Biotechnology, Nantong, China), and protein concentration was measured using the BCA kit (Beyotime Institute of Biotechnology). An equal amount of protein (40 μg per lane) was separated by SDS-polyacrylamide gel electrophoresis (PAGE) in 6%, 10%, and 12% acrylamide gels and transferred onto polyvinylidine difluoride (PVDF) membranes (Millipore Corporation, Billerica, USA). The membrane was blocked in 5% fat-free milk and incubated overnight at 4°C with the following primary antibodies: rabbit anti-OTUB1 (1:3000 dilution; Abcam, Cambridge, USA), rabbit anti-Bax (1:1000 dilution; Abcam), polyclonal rabbit anti-Caspase-3 (1:1000 dilution; Abcam), polyclonal rabbit anti-Caspase-9 (1:1000 dilution; Abcam), and monoclonal rabbit anti-Bcl-2 (1:500 dilution; Abcam). The secondary antibody was horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (1:1000; Beyotime Institute of Biotechnology). After stripping, the membrane was reprobed with antibody against β-actin (1:1000; Beyotime Institute of Biotechnology) overnight at 4°C, followed by incubation with secondary antibody as above at room temperature for 2 h. Bands were visualized using an enhanced chemiluminescence system (ECL; Beyotime Institute of Biotechnology). Data were quantified by densitometry.
Immunohistochemistry staining and evaluation of OTUB1 expression
We used a tissue microarray (TMA) system (Quick-Ray, UT06; UNITMA, Seoul, Korea) in the Department of Clinical Pathology of the Affiliated Hospital of Nantong University. Core tissue biopsies (2 mm in diameter) were taken from individual paraffin-embedded sections and arranged in recipient paraffin blocks. TMA specimens were cut into 4-μm sections and placed on super frost-charged glass microscope slides. TMA analysis was used as a quality control for hematoxylin and eosin staining. Tissue sections were deparaffinized and rehydrated in graded ethanol. Antigen retrieval was performed by boiling sections in ethylenediaminetetra-acetic acid buffer (pH 6.0) for 3 min in a pressure cooker. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide for 30 min. Sections were then incubated with a polyclonal antibody specific to OTUB1 (1:50 dilution; Abcam) at 4°C overnight, followed by incubation with a biotinylated anti-rabbit secondary antibody at 37°C for 30 min. Slides were then processed using horseradish peroxidase and 3,3-diaminobenzidine chromogen solution and counterstained with hematoxylin. Staining of OTUB1 in tumor and non-tumor tissues was examined in a blinded manner. Three fields were selected for examination of the proportion of positive cells and cell-staining intensity. Immunohistochemical staining was evaluated according to the immunoreactive score (IRS), which was assessed by the staining intensity and the proportion of positive cells. The intensity score was scored as follows: 0 (negative), 1 (weakly positive), 2 (moderately positive), and 3 (strongly positive). The quantity score documenting the proportion of OTUB1-positive cells was scored according to four categories: 1 (0%-25%), 2 (26%-50%), 3 (51%-75%), and 4 (76%-100%). Multiplication of intensity score and quantity score resulted in an IRS ranging from 0 to 12: samples with IRS 4-12 were defined as high OTUB1 expression, and samples with IRS 0-3 were defined as low OTUB1 expression.
RNA interference and transfection
Synthesized DNA nucleotide fragments (Sangon Biotech, Shanghai, China) encoding short hairpin RNA (shRNA) for the knockdown of endogenous OTUB1 were inserted into the pGPU6/GFP/Neo vector (GenePharma, Shanghai, China). The sequences of the shRNAs were as follows: OTUB1 shRNA-1, 5′-CTGAAGATGACAACATCTATC-3′; OTUB1 shRNA-2, 5′-CGTTCATGGACCTGATTGAGC-3′; OTUB1 shRNA-3, 5′-CTACGATATCCTCTACAAATA-3′; shRNA-NC (control), 5′-GTTCTCCGAACGTGTCACGT-3′. Cells were transfected using LipofectamineTM 2000 (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. The most effective silencing sequences were selected by western blot analysis and then each sequence was ligated into the pGPH1/GFP/Neo vector. Full-length OTUB1 cDNA was cloned into pCMV6/AC/GFP vector (OriGene, Rockville, USA). Two cell lines (HepG2 and HCCLM3) were separately transfected with plasmids and selected by GFP sorting. Cells were grown in complete medium containing 200 μg/ml G418 (Roche Diagnostics, Mannheim, Germany). Fluorescence microscopy was used to confirm the presence of the plasmids. Clones were separated and expanded for 4 weeks. Subclasses of cells expressing Neo and OTUB1 genes were named OTUB1-HepG2 and OTUB1-LM3.
Cell proliferation assay
The Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Shanghai, China) was used to stain cells at the indicated time point in accordance with the manufacturer's protocol to measure cell viability. The growth curve of HCC cells was evaluated by measurement of the absorbance at 450 nm. All experiments were performed in triplicate.
Transwell migration and invasion assays
For cell invasion assay, modified Boyden chambers consisting of matrigel-precoated membrane filter Transwell inserts with 8-μm pores were used in 24-well tissue culture plates (BD Biosciences, Bedford, USA). Cells (1 × 10 5 cells) from different groups were plated on the top of the chamber in DMEM without FBS and the bottom chamber was filled with DMEM containing 10% FBS as a chemoattractant. After 24 h of incubation in a 5% CO 2 humidified chamber at 37°C, non-invading cells were removed by wiping the upper surface of the membrane with a cotton swab and the filter membrane was fixed with 4% paraformaldehyde and stained with Exam MaSiLiang blue. The degree of invasion was quantified by counting the cells that had migrated through the membrane in at least six random fields per filter. Experiments were repeated three times in triplicate. For the analysis of cell migration, the above experiment was performed using modified Boyden chambers consisting of membrane filter Transwell inserts without precoated matrigel.
Statistical analysis
Statistical analyses were performed with SPSS 20.0 and Graphpad Prism 5.0 software. Quantitative data were expressed as the mean ± SD. Differences between two groups were analyzed by two-tailed Student's t-test. Categorical data were evaluated by the χ 2 test.
P value < 0.05 was considered statistically significant. All experiments were repeated in triplicate.
Results
OTUB1 expression in HCC tissues and cells
To investigate the role of OTUB1 in the progression of HCC, we examined OTUB1 protein expression in five randomly selected paired HCC specimens and four HCC lines (SK-hep1, HCCLM3, HepG2, and SMMC7721). Western blot analysis results revealed higher expression of OTUB1 in HCC tissues than in adjacent nontumor tissues (Fig. 1A) , and the HepG2 and HCCLM3 cell lines expressed higher levels of OTUB1 than SK-hep1 and SMMC7721 cell lines (Fig. 1B) . Then, the cellular expression of OTUB1 was also examined in HCC specimens and adjacent normal tissues of 115 matched samples by immunohistochemistry analysis. Compared to paired adjacent normal tissues, the expression of OTUB1 was dramatically higher in tumor tissues (Fig. 1C,D , P < 0.01).
Correlation of OTUB1 expression with clinicopathological features and outcomes
To determine the influence of OTUB1 on HCC progression, the correlation between OTUB1 expression and clinicopathological characteristics was investigated. The HCC patients were classified into two groups on the basis of the IHC results for OTUB1: high expression (IRS 4-12) and low expression (IRS 0-3). High OTUB1 expression was detected in 60/115 tumor tissues (52.2%), and low OTUB1 expression was observed in 55/115 tumor samples (47.8%). The association between OTUB1 expression and the clinicopathological outcomes is illustrated in Table 1 . It was found that high OTUB1 expression levels were related to TNM stage (P = 0.002), metastasis/recurrence (P = 0.016), and histology stage (P = 0.002), whereas there was no significant correlation between OTUB1 expression and patient age, gender, tumor location, tumor size, tumor number, or hepatitis B virus infection. These results showed that OTUB1 is overexpressed in HCC, and that OTUB1 functions as an oncogenic accelerator in HCC ( Table 1) .
Correlation between OTUB1 expression and patient survival
By differentiating patients with high and low OTUB1 expression, we investigated the prognostic effect of OTUB1 on the overall survival (OS) of HCC patients. By Kaplan-Meier curve assessment, patients with high OTUB1 expression were shown to have a significantly lower 5-year survival rate than those with low OTUB1 expression ( Fig. 2A , P = 0.001, log-rank test).
Univariate and multivariate analyses of prognostic variables in HCC patients
To investigate variables with potential prognostic significance, we performed univariate analysis of every variable according to the OS time of patients with HCC. Differences in predicting the prognosis were evaluated by determining the hazard ratio (HR) and P value of each variable. Next, the relative importance of each variable was examined using the Cox proportional hazards model. Multivariate stepwise regression analysis confirmed that significant prognostic factors for the OS of HCC patients were OTUB1 expression and histology stage. Therefore, multivariate analysis showed that OTUB1 protein expression has a significant correlation with poor prognosis of HCC patients as an independent prognostic factor ( Table 2 ).
The effect of OTUB1-silencing on the proliferation and migration of HCC cells
Next, the functional consequence capable of silencing OTUB1 in HCC cell lines was explored by comparing the effects of three different sequences of shRNA targeting OTUB1, a negative control shRNA, and a control without any intervention. Western blot analysis showed that OTUB1#2 was the most efficient sequence for silencing OTUB1 (Fig. 2B) . Therefore, OTUB1#2 was transfected into HepG2 and HCCLM3 cell lines, which showed the highest expression of OTUB1, to give HepG2-shOTUB1 and LM3-shOTUB1, respectively. Then the invasion, migration, and proliferation of these two experimental cell lines were assessed. Compared with the normal controls, significantly fewer HepG2-shOTUB1 and LM3-shOTUB1 cells migrated through the membrane in the migration chamber with or without the matrigel-precoated Transwells (Fig. 3A , P < 0.05) in the assay for invasion and migration. However, the proliferation ability of silenced cell lines HepG2-shOTUB1 and LM3-shOTUB1 was not significantly different ( Fig. 3B , P > 0.05). The results of these experiments show that OTUB1-silencing can effectively reduce the migration and invasion of HCC cells.
OTUB1 expression and apoptosis of HCC cells
To explore the intrinsic mechanism of OTUB1-induced growth of HCC cells, the expressions of apoptosis-related proteins after OTUB1-silencing were investigated. Our results showed that the expressions of apoptotic proteins Caspase-3, Caspase-9, and Bax in HepG2-shOTUB1 and LM3-shOTUB1 cells were higher than those in the normal controls, while the expression of the antiapoptotic protein Bcl-2 was reduced (Fig. 3C) , indicating that OTUB1-silencing might enhance apoptosis in HCC cells.
Discussion
Cancer is the major cause of death worldwide, and HCC is one of the leading causes of cancer-related deaths. Although surveillance and treatment strategies have been continuously improved in past decades, the prognosis of HCC remains unsatisfactory due to the high rate of recurrence and distant metastasis [27, 28] . At the current time, the general TNM stage and histological grading systems are used as prognostic indicators for HCC. However, even patients with the same TNM stage and/or histological grade of HCC can show a huge difference in tumor recurrence and metastasis. The prognostic variability of individuals with HCC can be attributed to heterogeneity of the tumor and the accumulation of genetic and epigenetic alterations [29] . A major cause of the poor prognosis in HCC is the absence of early diagnostic indicators and consequent late diagnosis; therefore, identifying novel and specific prognostic biomarkers for patients with early-stage HCC is crucial [30] . At present, alpha fetoprotein (AFP) is the most commonly applied serological marker for surveillance, diagnosis, and prediction of outcome in patients with HCC [31] [32] [33] . However, the diagnostic and prognostic sensitivity of AFP is unsatisfactory in the early stages of the disease; in particular, use of AFP indicators alone for the diagnosis and monitoring of patients with low levels of AFP often can not correctly diagnose HCC or reflect the progression of the disease, even when patients diagnosed with advanced HCC become clinically symptomatic [33] . Therefore, it is critically important to find markers that can predict the metastasis and recurrence of HCC. In this study, we showed that the expression level of OTUB1 is correlated with TNM stage, histology stage, recurrence and metastasis, and OS in HCC, suggesting that, in association with other markers, OTUB1 could serve as a biomarker for recurrence and metastasis and a prognostic factor for HCC. However, in this study the collected HCC samples were from a single clinical center, and therefore the results should be verified in the future by collecting HCC patient samples from a large number of clinical research centers. OTUB1 expression has been linked to prognosis in a variety of human malignancies, suggesting that it may act as a tumor oncogene. OTUB1 expression was found to be significantly increased in colorectal cancer [25] and increased levels of OTUB1 protein were reported in a subset of breast cancer [34] and gastric adenocarcinoma patients [35] . In this study, we showed for the first time that OTUB1 expression was significantly higher in HCC tissues than in the adjacent liver tissues by IHC analyses. Similar results were previously reported in colorectal cancer [25] . Our results showed increased expression of OTUB1 in 52.2% of HCC samples, and the up-regulated OTUB1 expression was significantly associated with TNM stage, histology stage and metastasis/recurrence. The relationship between a high expression of OTUB1 and metastasis/recurrence suggests that the high expression of OTUB1 may help accelerate the migration and invasion of tumor cells. These findings suggest that OTUB1 may be an oncogene promoting HCC progression and correlated with pathogenesis.
Importantly, Kaplan-Meier survival analyses showed that high OTUB1 expression was significantly correlated with poor OS. Furthermore, multivariate Cox regression analyses indicated that OTUB1 expression was an independent risk factor for OS, suggesting that the high expression of OTUB1 may help in the identification of HCC patients with poor prognosis. Laramas et al. [35] provided evidence for a strong association between high expression of OTUB1 and poor prognostic factors in human gastric adenocarcinoma patients. In addition, Zhou et al. [25] showed that overexpression of OTUB1 protein in colorectal cancer was associated with poor patient outcome. Together with these results, we showed that the expression level of OTUB1 was correlated with TNM stage, histology stage, recurrence/metastasis, and OS in HCC, suggesting that, in association with other markers, OTUB1 could serve as a biomarker for recurrence and metastasis, and a prognostic factor for HCC. Interestingly, TNM stage and metastasis are not independent predictors in multivariate analysis. This might be due to the limited sample size in this study, because the collected HCC samples were from a single clinical center. Therefore these results should be verified in the future by collecting HCC patient samples from a large number of clinical research centers.
In our study, immunohistochemistry results showed that increased OTUB1 expression was obviously correlated with tumor recurrence and OTUB1 enhanced tumor cell migration and invasion in the in vitro experiments, suggesting its role in promoting tumor progression. To further elucidate the role of OTUB1 in the tumorigenesis of HCC, we silenced the expression of OTUB1 in two HCC cell lines, HepG2 and HCCLM3, using shRNA. Proliferation assay confirmed that OTUB1-silencing could not inhibit cell growth in HepG2 and HCCLM3 cell lines. These results are in agreement with the results reported by Iglesias-Gato et al. [23] (Erratum: OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo. Mol Cancer 2015, 14: 88). In prostate cancer cells, they showed that OTUB1 depletion caused defects in cell invasion but not in proliferation. Whereas migration and matrigel invasion assays showed that it suppressed migration and invasion in vitro, indicating that OTUB1 plays a role in tumor metastasis. Our results suggest that silencing of OTUB1 might enhance apoptosis in HCC cells, and this should also be explored in future research.
In the present study, we found that OTUB1 markedly contributes to the pathogenesis and aggressive biology of HCC. Although we did not fully elucidate the mechanism of OTUB1 in the progression of HCC, we believe that it might prompt HCC cell invasion and migration by modulating the activity of the TGF-β pathway. The TGF-β signaling pathway plays an important role in promoting HCC [36] . Herhaus et al. [21] showed that OTUB1 improved TGF-β-mediated gene transcription through phosphorylation of SMAD2/3 and rescuing phospho-SMAD2/3 from proteasomal degradation. Poorly differentiated HCC cells responded to TGF-β; this correlated with recurrence and metastasis [37] , which are the most important biological characteristics of malignant cancer as well as a common cause of death in HCC patients and the main reason for the failure of HCC treatment [38] . Previous researches showed that FOXM1 facilitates cancer cell proliferation and protects cells from genotoxic agentsinduced cell death by improving DNA damage repair [39] [40] [41] . Karunarathna et al. [42] proved that OTUB1 can improve the proliferative rate by targeting FOXM1. FoxM1 overexpression promotes HCC cell proliferation by increasing the expression of cyclin B1 and cyclin D1 and reducing the expression of p27(Kip1) and p21(Cip1) [43] . Interestingly, OTUB1 is a c-IAP-interacting protein that can cleave K48-linked polyubiquitin chains from c-IAP1 and modulate IAP antagonist-stimulated proteasomal degradation of c-IAP1. TNFRmediated activation of NF-κB and MAPK pathways and the induction of gene expression are severely inhibited by degradation of c-IAP1 [44] . Therefore, we believe that OTUB1 might promote primary HCC proliferation, metastasis, and recurrence. However, whether OTUB1 is correlated with components of the classic EGFR-activated signal Figure 3 . Effect of OTUB1-silencing on cell proliferation, migration and invasiveness of hepatocellular carcinoma cells (A) Migration and invasion ability were presented as total number of cells that migrated to the bottom chamber of the Transwell without or with precoated matrigel, respectively, as calculated in at least six random fields per filter. Magnification, ×200. (B) The proliferation ability of two cell lines was examined using CCK-8 kit. Specifically, 5 × 10 3 cells were seeded in 100 μl of medium per well into 96-well plates (three wells per group). Then, 10 μl of CCK8 solution was added to the culture medium in each well after 24, 48, 72, and 96 h. Then cells were incubated for another 3 h. The absorbance was determined at 450 nm. (C) Western blot analysis of apoptosis-associated protein expression in OTUB1-silenced cells. β-Actin was used as the loading control. *P < 0.05, **P < 0.01. N.S., not significant.
transduction pathway, such as Ras-Raf-MAPK and PI3K-Akt, and thus play a biological role in the progression of HCC is still unclear. We will explore the mechanism of OTUB in liver cancer signaling pathways in the future. Furthermore, an important paralog of OTUB1 is OTUB2. OTUB2 and OTUB1 are similar in structure, and both function to remove conjugated ubiquitin from proteins in vitro and may therefore play an important regulatory role at the level of protein turnover by preventing degradation. OTUB2 mediates deubiquitination of Lys11-, Lys48-, and Lys63-linked polyubiquitin chains, with a preference for Lys-63-linked chains [45] . Li et al. [46] found that OTUB1 and OTUB2 negatively regulate virus-triggered type I interferon induction and the cellular antiviral response by deubiquitinating TRAF3 and TRAF6.
In conclusion, we have demonstrated for first time that OTUB1 protein expression is significantly increased in human HCC tissues, and provided clear evidence for the important role of OTUB1 in HCC development and metastasis. Moreover, we also showed that OTUB1 might be a novel adverse-independent prognostic factor for HCC and a useful biomarker for therapeutic efficacy in HCC treatment.
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